Shares of La Jolla USA-based biotech Equillium (Nasdaq EQ) were up 12% to $1.85 in pre-market trading, on news of a lucrative licensing deal with Japan’s Ono Pharmaceutical (TYO: 4528)
The companies have entered into an exclusive option and asset purchase agreement regarding Equillium’s rights to itolizumab, a first-in-class anti-CD6 monoclonal antibody, to which the US firm gained rights through an exclusive partnership with India’s Biocon.
Itolizumab is currently in a Phase III study for patients with acute graft-versus-host disease and in a Phase Ib study for patients with lupus nephritis
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze